Site Editor
Soo Park, MD
Soo Park, MD
Posted: Monday, September 9, 2024
Ketty Peris, MD, PhD, of Catholic University Fondazione Policlinico Universitario‐IRCCS, Rome, and colleagues conducted a health-related quality-of-life analysis of a cohort patients with metastatic basal cell carcinoma who were treated with the monoclonal antibody cemiplimab-rwlc in a multicenter phase II trial (ClinicalTrials.gov identifier NCT03132636). The results, which were published in the journal Cancer Medicine, indicated stability in patient‐reported outcomes.
“From baseline to cycle nine, most patients who received cemiplimab treatment maintained a low symptom burden while reporting maintenance or improvement in the European Organisation for the Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (QLQ‐C30) global health status/quality-of-life domain and on the functioning scale,” the investigators commented. “The benefits…were additionally demonstrated by maintenance of scores across the emotional, symptom, and functional subscales on the Skindex‐16.”
A total of 54 patients who were not candidates for continued Hedgehog inhibitor therapy were treated with 350 mg of intravenous cemiplimab every 3 weeks for five (9 weeks/cycle) and then four (12 weeks/cycle) cycles. They completed the QLQ‐C30 and Skindex‐16 questionnaires at baseline and on the first day of each cycle.
Based on the QLQ‐C30 scores, at baseline, patients reported low symptom burden and moderate-to-high functioning. The overall mean changes from baseline indicated maintenance for the QLQ‐C30 global health status/quality-of-life domain and across all functioning and symptom scales. The investigators reported clinically meaningful improvement or maintenance at cycle two for the global health status/quality-of-life domain (77%), functioning scales (77%–86%), and symptom scales (70%–93%); excluding fatigue, similar proportions of improvement or maintenance were documented at cycles six and nine.
Clinically meaningful improvement or maintenance was reported by more than a third of patients (range: 76%–88%) across the emotional, symptom, and functional subscales at cycle two; similar proportions were generally observed at cycles six and nine. The overall mean changes from baseline indicated maintenance across these subscales.
Disclosure: For full disclosures of the study authors, visit ncbi.nlm.nih.gov.
JNCCN Spotlights
Resources
For your Patients
